Form 8-K - Current report:
SEC Accession No. 0001104659-25-074741
Filing Date
2025-08-06
Accepted
2025-08-06 16:37:21
Documents
13
Period of Report
2025-08-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2522137d3_8k.htm   iXBRL 8-K 43119
2 EXHIBIT 99.1 tm2522137d3_ex99-1.htm EX-99.1 18369
  Complete submission text file 0001104659-25-074741.txt   240785

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epix-20250805.xsd EX-101.SCH 3020
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epix-20250805_lab.xml EX-101.LAB 34239
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epix-20250805_pre.xml EX-101.PRE 22362
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2522137d3_8k_htm.xml XML 3768
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)